Modeling longer-term efficacy of neratinib in the extended adjuvant setting for early-stage breast cancer.

e12011Background: Long-term efficacy in the extended adjuvant setting requires a long follow-up. In the ExteNET trial, neratinib was given for a year and invasive disease-free survival (iDFS) asses...